IL122215A - Dolastatin derivatives as antineoplastics and their preparation - Google Patents

Dolastatin derivatives as antineoplastics and their preparation

Info

Publication number
IL122215A
IL122215A IL12221596A IL12221596A IL122215A IL 122215 A IL122215 A IL 122215A IL 12221596 A IL12221596 A IL 12221596A IL 12221596 A IL12221596 A IL 12221596A IL 122215 A IL122215 A IL 122215A
Authority
IL
Israel
Prior art keywords
antineoplastics
preparation
dolastatin derivatives
dolastatin
derivatives
Prior art date
Application number
IL12221596A
Other languages
English (en)
Other versions
IL122215A0 (en
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of IL122215A0 publication Critical patent/IL122215A0/xx
Publication of IL122215A publication Critical patent/IL122215A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
IL12221596A 1995-06-07 1996-06-03 Dolastatin derivatives as antineoplastics and their preparation IL122215A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/472,453 US5831002A (en) 1992-05-20 1995-06-07 Antitumor peptides
PCT/EP1996/002392 WO1996040751A1 (en) 1995-06-07 1996-06-03 Novel dolastatin derivatives, their preparation and use

Publications (2)

Publication Number Publication Date
IL122215A0 IL122215A0 (en) 1998-04-05
IL122215A true IL122215A (en) 2001-08-26

Family

ID=23875567

Family Applications (2)

Application Number Title Priority Date Filing Date
IL12221596A IL122215A (en) 1995-06-07 1996-06-03 Dolastatin derivatives as antineoplastics and their preparation
IL12221696A IL122216A (en) 1995-06-07 1996-06-03 Dolastatin derivatives against cancer and their preparation

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL12221696A IL122216A (en) 1995-06-07 1996-06-03 Dolastatin derivatives against cancer and their preparation

Country Status (33)

Country Link
US (1) US5831002A (bg)
EP (2) EP0871656B1 (bg)
JP (2) JP3957751B2 (bg)
KR (2) KR100437985B1 (bg)
CN (2) CN1182153C (bg)
AR (2) AR003136A1 (bg)
AT (2) ATE224910T1 (bg)
AU (2) AU725164B2 (bg)
BG (2) BG102125A (bg)
BR (2) BR9609424A (bg)
CA (2) CA2219818C (bg)
CO (2) CO4700527A1 (bg)
CZ (2) CZ293682B6 (bg)
DE (2) DE69623472T2 (bg)
DK (2) DK0871656T3 (bg)
ES (2) ES2186783T3 (bg)
HR (2) HRP960277A2 (bg)
HU (2) HU228073B1 (bg)
IL (2) IL122215A (bg)
MX (2) MX9709146A (bg)
MY (2) MY119042A (bg)
NO (2) NO318384B1 (bg)
NZ (2) NZ310444A (bg)
PL (2) PL185762B1 (bg)
PT (2) PT871656E (bg)
RO (2) RO118953B1 (bg)
SI (2) SI0832104T1 (bg)
SK (1) SK282466B6 (bg)
TR (2) TR199701545T1 (bg)
TW (2) TW508357B (bg)
UA (2) UA46776C2 (bg)
WO (2) WO1996040751A1 (bg)
ZA (2) ZA964710B (bg)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
TW474946B (en) * 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
US20010009901A1 (en) * 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
US5965537A (en) * 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
US6103698A (en) 1997-03-13 2000-08-15 Basf Aktiengesellschaft Dolastatin-15 derivatives in combination with taxanes
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6015790A (en) * 1997-10-06 2000-01-18 Basf Aktiengesellschaft Methods and compositions for treating rheumatoid arthritis
US5985837A (en) * 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
EP1159273A1 (en) 1999-03-02 2001-12-05 Boehringer Ingelheim Pharmaceuticals Inc. Compounds useful as reversible inhibitors of cathepsin s
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
CA2445591A1 (en) 2001-04-27 2002-11-07 The Procter & Gamble Company Nitrogen heterocyclic compounds and compositions for controlling biofilms
WO2003051835A2 (en) * 2001-12-18 2003-06-26 Proteologics, Inc. Methods and compositions for the inhibition of viral release
EP1531846A4 (en) * 2002-02-27 2006-04-19 Us Gov Health & Human Serv CONJUGATES OF LIGAND, LINK AND CYTOTOXIC AGENS, AND RELATED COMPOSITIONS AND USE PROCESSES
EP1781310B1 (en) 2004-08-02 2015-10-14 Ramot at Tel Aviv University Ltd. Articles of peptide nanostructures and method of forming the same
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
US20080292616A1 (en) * 2005-08-19 2008-11-27 Government Of The United Of America, Represented By The Secretary, Department Of Health And.... Topical Formulations of Histone Deacetylase Inhibitors and Methods Using the Same
WO2007043048A2 (en) * 2005-10-11 2007-04-19 Ramot At Tel Aviv University Ltd. Self-assembled fmoc-ff hydrogels
EP2024362A4 (en) 2006-05-16 2012-01-25 Pharmascience Inc IAP BIR DOMAIN BINDING COMPOUNDS
CL2007002166A1 (es) * 2006-07-24 2008-01-25 Tetralogic Pharm Corp Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer.
WO2008127560A1 (en) * 2007-04-12 2008-10-23 Scinopharm Taiwan Ltd. Process for making galantamine
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
US9284350B2 (en) 2010-02-12 2016-03-15 Pharmascience Inc. IAP BIR domain binding compounds
JP2014502620A (ja) 2010-12-30 2014-02-03 エナンタ ファーマシューティカルズ インコーポレイテッド 大環状ｃ型肝炎セリンプロテアーゼ阻害剤
CN103380132B (zh) 2010-12-30 2016-08-31 益安药业 菲啶大环丙型肝炎丝氨酸蛋白酶抑制剂
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
EP3470413A3 (en) 2011-05-27 2019-08-07 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
JPWO2023033129A1 (bg) 2021-09-03 2023-03-09

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
EP0598129B1 (en) * 1991-08-09 2000-03-22 Teikoku Hormone Mfg. Co., Ltd. Novel tetrapeptide derivative
CZ292612B6 (cs) * 1992-05-20 2003-11-12 Abbott Gmbh & Co. Kg Peptid s protirakovinnou aktivitou, jeho použití a farmaceutický prostředek s obsahem takového peptidu
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters

Also Published As

Publication number Publication date
BR9609423A (pt) 1999-06-29
MY119042A (en) 2005-03-31
WO1996040752A1 (en) 1996-12-19
MX9709146A (es) 1998-03-31
TW508357B (en) 2002-11-01
UA46775C2 (uk) 2002-06-17
CA2219819A1 (en) 1996-12-19
SK282466B6 (sk) 2002-02-05
NO318384B1 (no) 2005-03-14
DE69623992T2 (de) 2003-05-22
HU228073B1 (hu) 2012-09-28
BG102125A (bg) 1998-09-30
DE69623472D1 (de) 2002-10-10
PL185763B1 (pl) 2003-07-31
BR9609424A (pt) 2000-03-28
AU6124296A (en) 1996-12-30
HRP960257A2 (en) 1998-02-28
US5831002A (en) 1998-11-03
AR003427A1 (es) 1998-08-05
HU228071B1 (hu) 2012-09-28
HRP960277A2 (en) 1997-10-31
AU725164B2 (en) 2000-10-05
ZA964710B (en) 1997-12-08
EP0871656A1 (en) 1998-10-21
SI0871656T1 (en) 2003-08-31
AU725170B2 (en) 2000-10-05
ES2188759T3 (es) 2003-07-01
DE69623472T2 (de) 2003-08-21
CA2219818C (en) 2008-05-20
RO119783B1 (ro) 2005-03-30
CZ376597A3 (cs) 1998-06-17
NZ310444A (en) 1999-11-29
EP0871656B1 (en) 2002-09-25
MX9709147A (es) 1998-03-31
PL323723A1 (en) 1998-04-14
JP4221062B2 (ja) 2009-02-12
AU6124196A (en) 1996-12-30
HUP9801817A2 (hu) 1998-11-30
ZA964711B (en) 1997-12-08
CO4700527A1 (es) 1998-12-29
EP0832104A1 (en) 1998-04-01
CZ293683B6 (cs) 2004-07-14
PL323726A1 (en) 1998-04-14
CZ293682B6 (cs) 2004-07-14
CA2219818A1 (en) 1996-12-19
NO975710D0 (no) 1997-12-05
KR100437986B1 (ko) 2004-09-18
AR003136A1 (es) 1998-07-08
ATE223431T1 (de) 2002-09-15
TW424096B (en) 2001-03-01
CN1182154C (zh) 2004-12-29
DK0871656T3 (da) 2003-01-27
CN1182153C (zh) 2004-12-29
RO118953B1 (ro) 2004-01-30
JPH11504652A (ja) 1999-04-27
PL185762B1 (pl) 2003-07-31
NZ310443A (en) 1999-10-28
KR19990022583A (ko) 1999-03-25
CO4700526A1 (es) 1998-12-29
IL122216A (en) 2002-02-10
JPH11504653A (ja) 1999-04-27
SI0832104T1 (en) 2003-08-31
CA2219819C (en) 2008-05-20
DE69623992D1 (de) 2002-10-31
IL122215A0 (en) 1998-04-05
CZ376397A3 (cs) 1998-06-17
IL122216A0 (en) 1998-04-05
WO1996040751A1 (en) 1996-12-19
CN1187198A (zh) 1998-07-08
DK0832104T3 (da) 2003-01-06
TR199701545T1 (xx) 1998-04-21
KR19990022582A (ko) 1999-03-25
NO317670B1 (no) 2004-11-29
PT871656E (pt) 2002-12-31
NO975710L (no) 1998-02-02
HUP9801910A3 (en) 1999-06-28
JP3957751B2 (ja) 2007-08-15
BG102152A (bg) 1998-09-30
ATE224910T1 (de) 2002-10-15
KR100437985B1 (ko) 2004-09-18
EP0832104B1 (en) 2002-09-04
SK165397A3 (en) 1998-10-07
PT832104E (pt) 2002-12-31
MY124487A (en) 2006-06-30
UA46776C2 (uk) 2002-06-17
HUP9801817A3 (en) 1999-06-28
CN1187199A (zh) 1998-07-08
TR199701544T1 (xx) 1998-03-21
NO975711L (no) 1998-01-30
NO975711D0 (no) 1997-12-05
HUP9801910A2 (hu) 1999-01-28
ES2186783T3 (es) 2003-05-16

Similar Documents

Publication Publication Date Title
IL122215A (en) Dolastatin derivatives as antineoplastics and their preparation
IL116851A0 (en) 3-arylidene-2-oxindole derivatives their preparation and use
IL118825A (en) Substituted 6-dimethylaminomethyl-1-phenyl-cyclohexane derivatives their preparation and use
IL114795A0 (en) N-benzylindole- and benmzopyrazole derivatives their preparation and use
AP9600816A0 (en) Substituted N-indole-2-carbonyl)-B-alanimamides and derivatives as antidiabetic agents
IL119864A0 (en) 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-OL compounds their preparation and use
IL118442A0 (en) Triazolymethyl-cyclopentanols their preparation and use
IL121298A0 (en) N-(4-aryl-thiazol-2-YL)-sulphonamide derivatives and their uses
IL116139A0 (en) Pyrrole derivatives their preparation and use
IL118441A0 (en) Triazolymethyl-oxiranes their preparation and use
IL123611A0 (en) Novel amino acid derivatives their preparation and use
IL116525A0 (en) Piperazinedione derivatives their preparation and use
ZA967800B (en) Heteroaryllsubstituted acryloylguanidine derivatives and pharmaceutical compositions comprising them
IL118119A0 (en) Azacycloalkane derivatives their preparation and their application in therapy
HUP9602196A3 (en) Sulfonyl- and sulfinyl-benzoyl-guanidine derivatives and pharmaceutical compositions thereof
GB9705035D0 (en) Indolyl-pyrrolydenemethylpyrrole derivatives and process for their preparation
IL118443A0 (en) Cycloalkane-benzylidene derivatives their preparation and use
ZA943649B (en) Piperidine derivatives their preparation and use
IL123092A0 (en) Pyrazol-4-ylbenzoyl derivatives their preparation and use
IL122686A0 (en) Benzylhydroxylamines their preparation and use
IL118444A0 (en) Mercapto-triazolyl-silanes their preparation and use
IL118629A (en) N-substituted CIS-N-propenyl-acetamides and their preparation
IL118781A0 (en) Preparation of N-protected 4-ketoproline derivatives
AU6298196A (en) Tetrahydro-betacarboline derivatives and their preparation and use
IL118547A0 (en) Aqueous film-formimg compositions and their use

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
HP Change in proprietorship
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired